Researchers have uncovered how BAP1 functions at the molecular level and present a novel therapeutic strategy to slow cancer progression. BAP1's role in DNA repair pathways and its potential as a biomarker for personalized treatment are also explored.
SourceSingHealth·JournalScience Translational Medicine·TypeExperimental study·DateApr 1, 2026
A new study reveals how a promising Parkinson's drug works by inhibiting the enzyme USP30, which prevents damaged mitochondria from being degraded. This breakthrough could lead to targeted therapies for Parkinson's disease and chronic kidney disease.
SourceMax Planck Institute of Molecular Physiology·JournalNature Structural & Molecular Biology·TypeExperimental study·DateMay 8, 2025
Researchers have identified two new deubiquitinases, USP53 and USP54, which play a crucial role in removing polyubiquitin tags from proteins. This study suggests that mutations in the USP53 gene are associated with paediatric cholestasis, highlighting the potential for targeted treatment.
SourceMax Planck Institute of Molecular Physiology·JournalNature Chemical Biology·TypeExperimental study·DateDec 19, 2024